智通财经APP获悉，日前，"AI+慢病管理"头部企业方舟健客(06086)自主研发的AI超级大脑——"杏捷大模型"在国家网信 办完成生成式人工智能服务备案(备案号：Guangdong-XingJie-202509120089)。10月31日，"备案赋能 粤创未来"广东省备 案大模型发布会(第一期)在深圳成功举行，方舟健客获颁发"生成式人工智能服务备案证明"。 图/方舟健客获颁发"生成式人工智能服务备案证明" 方舟健客创始人、董事长兼首席执行官谢方敏博士在发布会上表示，杏捷大模型的成功问世，是方舟健客在"AI+慢病管 理"领域的又一次重要实践。"真正的AI赋能，从来不是追求功能堆砌，而是让健康关怀变得主动、有预见、无处不 在。"立足这一起点， 方舟健客未来将不断丰富AI+H2H(Hospital To Home，从医院到家庭)智慧医疗服务新生态(以下简称 AI+H2H生态)，致力于将前沿AI技术与专业医疗服务深度融合，让每一位用户都能享受到更智能、更便捷、更个性化的健 康服务。 "杏捷大模型"完成国家级备案，标志着慢病管理服务领域正式从传统的被动问答式服务，迈入以AI为核心的主动洞察与个 性化解决方案驱动的新时 ...

Core Insights - The strategic partnership between Ark Health (方舟健客) and Fosun Pharma (复星医药) aims to enhance chronic disease management, particularly focusing on psoriasis, through AI technology and digital health solutions [1][2][3] Group 1: Strategic Collaboration - The collaboration will leverage AI and digital marketing to create a comprehensive management system for chronic diseases, starting with psoriasis [1][2] - Both companies will engage in academic and public awareness initiatives, utilizing AI to improve disease understanding and long-term management [1][2][3] Group 2: AI Integration in Disease Management - Ark Health will implement its AI health management model to provide personalized recovery advice and continuous tracking for psoriasis patients [2][5] - The partnership will also feature an AI medication assistant offering 24/7 consultation, ensuring scientific and safe management of psoriasis [2][3] Group 3: Public Engagement and Education - The launch of the "AI + New Perspectives on Psoriasis Management" public awareness week aims to enhance health literacy through AI-driven content [4][5] - The initiative has already attracted over a million viewers on its first day, showcasing the effectiveness of AI in health education [4][5] Group 4: Future Prospects - The collaboration is expected to expand beyond psoriasis to other chronic diseases, contributing to the broader goal of improving health management in China [5][7] - Ark Health's strategic vision includes developing an "AI+" ecosystem for chronic disease management, with ongoing projects in weight management and other areas [5][7]

Core Insights - The strategic partnership between Ark Health and Fosun Pharma aims to enhance chronic disease management, particularly focusing on psoriasis through AI technology [1][2] - The collaboration will leverage both companies' strengths to create a comprehensive management system for psoriasis patients, addressing existing challenges in traditional management methods [2][4] Group 1: Strategic Collaboration - Ark Health and Fosun Pharma signed a strategic cooperation agreement to work closely in the "AI + Chronic Disease Management" sector, focusing on autoimmune diseases like psoriasis [1] - The partnership will involve deep academic collaboration, digital marketing, and the application of AI technology to improve disease awareness, intervention, and long-term management [1][2] Group 2: AI Integration in Disease Management - The collaboration will utilize Ark Health's AI health manager to provide personalized rehabilitation recommendations and continuous tracking for psoriasis patients [2] - An AI medication assistant will offer 24/7 medication consultation, ensuring scientific and safe management of psoriasis [2] Group 3: Public Awareness and Education - The "AI + New Perspectives on Psoriasis Management" public awareness week was launched, utilizing AI technology to enhance health education efficiency and quality [2][4] - The initiative aims to transform health education from a one-way communication model to a user-centered, data-driven, and sustainable interaction approach [4] Group 4: Future Prospects - The partnership is expected to expand beyond psoriasis management to cover a broader range of chronic diseases, contributing to the development of a robust health management ecosystem in China [4] - Ark Health's strategic vision includes the acceleration of its "AI +" ecosystem blueprint, with plans to implement similar innovative models in other chronic disease management areas [4]

智通财经APP获悉，10月29日"世界银屑病日"到来之际，方舟健客(06086)与复星医药(02196)战略合作签约仪式在上海隆重举行。方舟健客创始人、董事长 兼首席执行官谢方敏博士，与联袂出席的复星医药国内营销平台联席CEO李梅、旗下新零售事业部负责人黄佳国，共同签署战略合作协议。 方舟健客创始人、董事长兼首席执行官谢方敏博士表示："很高兴能与复星医药达成战略合作，这不仅是双方优势资源共享，也标志着我们的AI战略正从技 术能力建设，走向与产业伙伴共创价值的阶段。期待以此次合作为良好开端，我们共同打造出'AI+银屑病管理'的新范式，并将这一模式拓展至更广泛的疾 病领域，惠及更多患者。" 签约仪式后，方舟健客宣布，"AI+银屑病管理新视野"科普宣传周（下称：宣传周）今日正式启动。宣传周借助AI技术，为健康科普带来效率、质量的创新 突破。直播首日便吸引超百万人次观看，充分展现了AI赋能的健康科普对于公众的吸引力。 本次宣传周，将为一众用户带来系列视频直播。值得一提的是，AI能力将贯穿全程——直播前，平台将通过AI技术分析用户关切的话题，并辅助内容精准 定制；在直播互动与后续服务中，AI技术将进一步优化信息传播及触 ...

Core Insights - The "AI + Weight Management" transformation is emerging as a critical public health issue in China, driven by severe obesity problems among residents and supported by national policies [1][2][3] - The "AI + Weight Management" sector is poised for explosive growth, with increasing consumer demand for scientific and sustainable weight loss solutions, and strong policy backing from the government [2][6] - Ark Health has established a competitive edge in the "AI + Weight Management" space through its integrated "AI + H2H" ecosystem, which connects users, doctors, and pharmaceutical companies [4][5] Policy and Market Demand - The Chinese government has initiated several policies to promote weight management, including the launch of a "Weight Management Year" in 2024 and the incorporation of health weight management into national public health governance by 2025 [2][3] - There is a significant market demand for personalized and continuous weight loss interventions, which aligns well with AI's capabilities in data analysis and real-time feedback [2][4] Technological Advancements - Ark Health has developed an innovative "AI + Weight Management" digital solution that addresses common challenges in weight loss, such as fragmented plans and safety concerns, by utilizing its proprietary AI models [4][5] - The platform connects 229,000 practicing doctors, over 52.8 million users, and 980 pharmaceutical companies, creating a comprehensive network that enhances service delivery [5][6] Business Model and Financial Performance - Ark Health's business model has shown strong potential for profitability, with a high repurchase rate of 85.4% among paying users and a 34.4% year-on-year increase in monthly active users [6][8] - The company achieved a net profit of 12.5 million yuan in mid-2025, marking a significant milestone in its journey towards profitability [6][8] Future Outlook - The "AI + Weight Management" sector is entering a critical phase of large-scale implementation, with Ark Health positioned as a leader due to its validated business model and technological advantages [8][9] - The company aims to expand its application scenarios and collaborate with various sectors to build a comprehensive weight management service system, contributing to national health goals [8][9]

Core Insights - The "AI + Weight Management" transformation is emerging as a critical public health issue in China, driven by severe obesity problems among residents and supported by national policies aimed at strategic weight management [1][2][9] - The "AI + Weight Management" sector is poised for explosive growth, with increasing consumer demand for scientific and sustainable weight loss solutions, and AI's capabilities aligning well with the need for personalized interventions [2][9] - Ark Health, as a pioneer in AI + chronic disease management, has established a validated business model and technological capabilities that fit within China's healthcare system, enhancing service efficiency and creating a closed-loop between diagnosis and medication [3][5] Industry Developments - The Chinese government has initiated policies to promote weight management, including the launch of a "Weight Management Year" in 2024 and the integration of health weight management into national public health governance by April 2025 [2][9] - The market for weight management solutions is expanding rapidly, with a strong willingness to pay among consumers for effective and scientifically-backed weight loss programs [2][6] Company Positioning - Ark Health has developed a unique "AI + H2H" ecosystem that connects users, doctors, and pharmaceutical companies, enhancing operational efficiency and addressing common pain points in weight management [4][5] - The company has built a robust network, connecting 229,000 practicing doctors, over 52.8 million users, and more than 980 pharmaceutical companies, facilitating personalized solutions and efficient service delivery [5][6] Financial Performance - Ark Health's platform shows strong user engagement, with an 85.4% repurchase rate among paying users and a 34.4% year-on-year increase in monthly active users, indicating a healthy ecosystem and significant commercial potential [6][9] - The company achieved profitability in mid-2025, with a net profit of 12.5 million yuan and an adjusted net profit growth of 16.8% year-on-year, validating the effectiveness of its "AI + H2H" ecosystem [6][9] Future Outlook - The "AI + Weight Management" sector is entering a critical phase of large-scale implementation, with Ark Health positioned as a leader due to its proven business model and technological advantages [8][9] - The company aims to expand its application scenarios and collaborate with various sectors to build a comprehensive weight management service system, contributing to national health goals [8][9]

Core Insights - The "Healthy China: AI + Weight Management" industry collaborative innovation seminar was successfully held, marking a significant step towards standardization and innovation in the weight management sector [1][4][16] - The seminar initiated a nationwide action to promote scientific weight loss, establishing the first national academic exchange platform in this field [4][16] Group 1: Industry Context - The scale of overweight and obesity in China is continuously expanding, with 11.98% of cardiovascular disease deaths attributed to high BMI in 2019 [5] - By 2030, medical costs related to overweight and obesity are projected to reach 418 billion yuan, accounting for approximately 21.5% of total medical expenses in China [5] Group 2: AI and Weight Management - AI technology is seen as a necessary trend in the weight management field, with the potential to address issues such as data security and algorithm ethics [5][7] - The seminar emphasized the need for a national-level communication platform to facilitate collaboration among research, academia, industry, and regulatory bodies [7] Group 3: Collaborative Initiatives - The seminar launched the "Healthy China: AI + Weight Management" nationwide promotion action, calling for the establishment of a scientific weight loss ecosystem [4][14] - Experts highlighted the importance of integrating cultural and technical approaches in weight management, advocating for community engagement through activities like group exercises [10][11] Group 4: Corporate Innovations - Fangzhou Jianke's CEO shared insights on the company's AI-driven weight management solutions, emphasizing personalized behavior interventions as a key area for AI application [11][12] - The company has developed the first "AI + Weight Loss" digital solution, which connects users with AI health assistants for personalized weight loss advice and 24/7 online consultation [12] Group 5: Future Outlook - The seminar's outcomes are expected to drive high-quality development in the health industry, contributing to the "Healthy China 2030" goal [16]

Core Insights - The article discusses the innovative use of AI technology by Fangzhou Jianke's Xing Shi Medical model to address chronic disease management, aiming to provide patients with a reliable and professional "familiar doctor" experience [1][5][10] - The recognition of this AI tool by the prestigious journal Nature signifies a shift in the global scientific community's perception of China's capabilities in healthcare AI applications [5][10] Group 1: AI and Chronic Disease Management - Fangzhou Jianke's approach focuses on enhancing the "trust" element in doctor-patient relationships, leveraging AI as an efficient tool to improve chronic disease management [3][4] - The AI model has saved over 60,000 hours of work for doctors and reduced patient wait times for consultations by over 70% [4] Group 2: Market Context and Challenges - The global healthcare system faces a "trilemma" of balancing quality, accessibility, and cost, particularly evident in China where a significant portion of the elderly population suffers from chronic diseases [5][6] - The company aligns its innovations with national policies aimed at digital transformation in the healthcare sector, emphasizing the importance of AI in enhancing public health [6] Group 3: Technological and Business Innovations - The underlying technology of the Xing Shi Medical model integrates various capabilities such as image and voice recognition, natural language processing, and extensive medical knowledge storage, achieving state-of-the-art performance [6][8] - Fangzhou Jianke has demonstrated sustainable profitability, with reported revenues of 2.707 billion yuan in 2024 and a net profit increase of 139% year-on-year [8][9] Group 4: Global Implications and Collaborations - The collaboration with leading pharmaceutical companies indicates a shift towards a new paradigm of "AI + chronic disease management," enhancing the global industry's endorsement of this Chinese solution [8][9] - The recognition from the capital market reflects the potential of Fangzhou Jianke's model to address the healthcare trilemma effectively [9] Group 5: Societal Impact and Future Outlook - The Xing Shi Medical model is positioned as a socially significant solution aimed at improving public health, with a focus on creating a collaborative ecosystem among patients, doctors, and industry partners [10][11] - The projected growth of China's digital chronic disease management market to 655 billion yuan by 2030 highlights the potential for further innovations in this sector [11]

Core Insights - The article emphasizes that chronic disease management in China is entering a new era driven by AI, highlighting the importance of technology in addressing healthcare challenges posed by an aging population [1][2] - The online chronic disease management market in China is projected to grow significantly, with a compound annual growth rate of 44.5%, from 45.5 billion yuan in 2023 to 600 billion yuan by 2030 [1] - Ark Health's AI-driven approach aims to create a patient-centered healthcare model, leveraging technology to enhance doctor-patient relationships and improve service efficiency [2][3] Technology Development - Ark Health's "Xing Shi Medical Model" is designed to integrate various intelligent components into a collaborative service team, aiming for state-of-the-art performance [3] - The AI assistant has reportedly saved doctors over 60,000 hours of time through its diagnostic and case analysis capabilities [3] - The company has developed five core AI products, including AI Medication Finder and AI Health Manager, which aim to enhance clinical decision-making and knowledge dissemination [4] Strategic Collaborations - Ark Health has formed strategic partnerships with pharmaceutical companies, such as Innovent Biologics, to target the rapidly growing weight management market, which is expected to reach 149 billion yuan by 2030 [6][7] - The collaboration with Innovent focuses on integrating AI technology with innovative weight loss products, providing comprehensive support for patients [6][8] - The partnership with Zhejiang Otsuka Pharmaceutical aims to enhance drug service offerings and health education through AI capabilities [7][8]

Core Insights - Fangzhou Jianke has achieved profitability with a revenue of 1.494 billion yuan, marking a 12.9% growth, and a net profit of 12.5 million yuan as of mid-2025 [3] - The company employs a "familiar doctor-patient" model, focusing on relationship reconstruction rather than merely chasing traffic [4][5] - The AI-powered "Xing Shi Medical Model" aims to enhance the efficiency of its H2H (Hospital to Home) healthcare ecosystem [6][9] Company Performance - Fangzhou Jianke's user base has grown to over 52.8 million registered users and 229,000 registered doctors by mid-2025, with a high repurchase rate of 84.7% among paying users [4] - The company’s growth is driven by value-based internal growth, reducing reliance on continuous traffic purchases [5] AI Integration - The "Xing Shi Medical Model" integrates a comprehensive knowledge base from the Chinese Medical Association, covering over 1.1 million articles across 170 core journals [6] - Five core AI products have been launched, creating a collaborative network across medical, patient, and enterprise sectors [7] Efficiency Improvements - The AI Doctor Assistant has saved over 60,000 hours of work for doctors by providing nearly 400,000 technical assists, allowing them to focus on more complex diagnoses [8] - The AI Health Manager has reduced average consultation times by over 70%, significantly enhancing patient experience [8] Future Vision - By 2025, the company aims to integrate AI assistants into daily medical practices, with daily usage exceeding 100,000 times [10] - The ultimate goal is to establish "Fangzhou Medical Smart Cloud" by 2027, serving as an authoritative clinical decision standard across the industry [10]